Search
Search
About
Log in
Join
Experiences with
Enzalutamide
Posts
Communities
777 public posts
Filter results
mcrpc , stage iv with aggressive treatments
right now he is following same Eligard 6 monthly and instead of bicalutamide he was prescribed 3 tablets
enzalutamide
daily. Fingers crossed .. will keep updating.Wish everyone all the courage and blessings to fight it out.
right now he is following same Eligard 6 monthly and instead of bicalutamide he was prescribed 3 tablets
enzalutamide
daily. Fingers crossed .. will keep updating.Wish everyone all the courage and blessings to fight it out.
caretkr
in
Advanced Prostate Cancer
6 years ago
It's Half Time at the Chemo Bowl - I am in front right now
MO advises that next treatments are likely to be hormonal - abiraterone or
enzalutamide
I guess. But since I am already hormone-independent I don't know how much this will help. Since I failed ADT within 3 months I asked MO if I have ARV7 splice variant.
MO advises that next treatments are likely to be hormonal - abiraterone or
enzalutamide
I guess. But since I am already hormone-independent I don't know how much this will help. Since I failed ADT within 3 months I asked MO if I have ARV7 splice variant.
Hazard
in
Advanced Prostate Cancer
6 years ago
[177Lu]-PSMA-617 Has Activity in Castration-Resistant Prostate Cancer
Violet, and colleagues evaluated the efficacy and safety of LuPSMA in a prospective phase II trial of 30 patients with metastatic castration-resistant prostate cancer who had progressed after standard therapies including taxane-based chemotherapy and second-generation antiandrogens (abiraterone or
enzalutamide
Violet, and colleagues evaluated the efficacy and safety of LuPSMA in a prospective phase II trial of 30 patients with metastatic castration-resistant prostate cancer who had progressed after standard therapies including taxane-based chemotherapy and second-generation antiandrogens (abiraterone or
enzalutamide
tango65
in
Advanced Prostate Cancer
6 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Cross-resistance between Ethinylestradiol and Enzalutamide
Cross-resistance between ethinylestradiol and
enzalutamide
was clearly observed in the setting of pre-docetaxel. In multivariate analysis, the T stage and number of therapies before
enzalutamide
were the only significant predictors of prostate-specific antigen response to
enzalutamide
.
Cross-resistance between ethinylestradiol and
enzalutamide
was clearly observed in the setting of pre-docetaxel. In multivariate analysis, the T stage and number of therapies before
enzalutamide
were the only significant predictors of prostate-specific antigen response to
enzalutamide
.
pjoshea13
in
Advanced Prostate Cancer
6 years ago
Olaparib/Durvalumab Combo Shows Promise in mCRPC
“But emerging data suggest potential activity in combinations, as seen with results reported with
enzalutamide
(Xtandi) plus pembrolizumab (Keytruda) and with a DNA-based vaccine plus pembrolizumab.”
“But emerging data suggest potential activity in combinations, as seen with results reported with
enzalutamide
(Xtandi) plus pembrolizumab (Keytruda) and with a DNA-based vaccine plus pembrolizumab.”
JLS1
in
Advanced Prostate Cancer
6 years ago
Quality of Life in Second-Line Treatment of Metastatic Castration-Resistant Prostate
At the time of study,
Enzalutamide
was not yet licensed in Switzerland so not included. It's a very interesting article so thought I would share it. http://www.clinical-genitourinary-cancer.com/article/S1558-7673(17)30244-6/pdf
At the time of study,
Enzalutamide
was not yet licensed in Switzerland so not included. It's a very interesting article so thought I would share it. http://www.clinical-genitourinary-cancer.com/article/S1558-7673(17)30244-6/pdf
Hidden
in
Advanced Prostate Cancer
6 years ago
Is AR-V7 Testing Pointless?
Neither abiraterone nor
enzalutamide
can have therapeutic activity against AR-V7 cells.
Neither abiraterone nor
enzalutamide
can have therapeutic activity against AR-V7 cells.
pjoshea13
in
Advanced Prostate Cancer
6 years ago
No longer prostate cancer
This explains why I failed to get benefit from Provenge or
Enzalutamide
. The rapid change occurred since August when a PET scan showed the growth of tumors in my mediastinum and left pleural space. They have now become very aggressive and are producing fluid rapidly.
This explains why I failed to get benefit from Provenge or
Enzalutamide
. The rapid change occurred since August when a PET scan showed the growth of tumors in my mediastinum and left pleural space. They have now become very aggressive and are producing fluid rapidly.
DenDoc
in
Advanced Prostate Cancer
6 years ago
Ralaniten [EPI-506]
mentions Ralaniten (aka EPI-506) as a: "novel first-in-class drug ... which binds to a unique region in the N-terminus domain of both the full-length and the truncated constitutively active splice variants of the AR, {&} is currently in clinical trials for patients who previously received abiraterone,
enzalutamide
mentions Ralaniten (aka EPI-506) as a: "novel first-in-class drug ... which binds to a unique region in the N-terminus domain of both the full-length and the truncated constitutively active splice variants of the AR, {&} is currently in clinical trials for patients who previously received abiraterone,
enzalutamide
pjoshea13
in
Advanced Prostate Cancer
6 years ago
ASCO Genitourinary Cancers Symposium (Phase II study of enzalutamide monotherapy with radiation therapy for intermediate risk PCa)
Testosterone and free testosterone levels rose significantly on
enzalutamide
therapy. Conclusions:
Enzalutamide
monotherapy with RT may be as effective as castrating ADT, and associated with fewer side effects.
Testosterone and free testosterone levels rose significantly on
enzalutamide
therapy. Conclusions:
Enzalutamide
monotherapy with RT may be as effective as castrating ADT, and associated with fewer side effects.
pjoshea13
in
Advanced Prostate Cancer
6 years ago
Finally, Real Promise' for Prostate Cancers With No Therapy20+-Month Improvement in Metastasis-Free Survival
In the PROSPER study, eligible men were also randomly assigned in a 2:1 ratio to receive either
enzalutamide
160 mg or placebo.
In the PROSPER study, eligible men were also randomly assigned in a 2:1 ratio to receive either
enzalutamide
160 mg or placebo.
Hidden
in
Advanced Prostate Cancer
6 years ago
Recent article about Lutetium 177 treatment in advanced mCRPC by doctors at the Technical University of Munich
Eligibility criteria for 177Lu-PSMA-I&T therapy included previous treatment with abiraterone or
enzalutamide
, previous taxane-based chemotherapy or unsuitability for taxanes as well as positive 68Ga-PSMA tracer uptake of metastases in a prior PET-scan.
Eligibility criteria for 177Lu-PSMA-I&T therapy included previous treatment with abiraterone or
enzalutamide
, previous taxane-based chemotherapy or unsuitability for taxanes as well as positive 68Ga-PSMA tracer uptake of metastases in a prior PET-scan.
Hidden
in
Advanced Prostate Cancer
6 years ago
Apalutamide - SPARTAN versus Enzalutamide - PROSPER.
term=
Enzalutamide
+PROSPER&rank=1 [4] https://www.clinicaltrials.gov/ct2/show/NCT01946204?term=Apalutamide+SPARTAN&rank=1
term=
Enzalutamide
+PROSPER&rank=1 [4] https://www.clinicaltrials.gov/ct2/show/NCT01946204?term=Apalutamide+SPARTAN&rank=1
pjoshea13
in
Advanced Prostate Cancer
6 years ago
Interesting result for BRCA patients from ASCO2018
"Effect of germline DNA repair gene mutations on outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and
enzalutamide
."
"Effect of germline DNA repair gene mutations on outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and
enzalutamide
."
snoraste
in
Advanced Prostate Cancer
6 years ago
New Memberas
Currently on
Enzalutamide
with fingers crossed!
Currently on
Enzalutamide
with fingers crossed!
PeturB
in
Advanced Prostate Cancer
6 years ago
Advanced metastatic protate cancer but still hoping.
Plus daily intake of
enzalutamide
. I have been on other medications but they have failed my PSA started to rise and then I've tried a new drug which put it back down again at the moment
enzalutamide
appears to be the best one so far for me.
Plus daily intake of
enzalutamide
. I have been on other medications but they have failed my PSA started to rise and then I've tried a new drug which put it back down again at the moment
enzalutamide
appears to be the best one so far for me.
GarawayGhd
in
Advanced Prostate Cancer
6 years ago
Is anyone else on the Enzalutamide and LY3023414 clinical trial?
My husband has been on the xtandi phase 2 trial a short time and his PSA is dropping. It went from 21 to 3 in ten days. So far, so good. The fatigue and bone pain have increased. It is not stopping my husband though. I am looking to compare notes with someone else on the trial Thank you to all the
My husband has been on the xtandi phase 2 trial a short time and his PSA is dropping. It went from 21 to 3 in ten days. So far, so good. The fatigue and bone pain have increased. It is not stopping my husband though. I am looking to compare notes with someone else on the trial Thank you to all the
StephjoeSteph4197
in
Advanced Prostate Cancer
6 years ago
ASCO Genitourinary Cancers Symposium [PROSPER].
Abstract: https://gucasym.org/sites/gucasym.org/files/GU18-Prostate-Cancer-Localized-Disease.pdf -Patrick 3 Oral Abstract Session, Thu, 1:00 PM-2:30 PM and Poster Session (Board #A4), Thu, 11:30 AM-1:00 PM and 5:15 PM-6:15 PM PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of
enzalutamide
Abstract: https://gucasym.org/sites/gucasym.org/files/GU18-Prostate-Cancer-Localized-Disease.pdf -Patrick 3 Oral Abstract Session, Thu, 1:00 PM-2:30 PM and Poster Session (Board #A4), Thu, 11:30 AM-1:00 PM and 5:15 PM-6:15 PM PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of
enzalutamide
pjoshea13
in
Advanced Prostate Cancer
6 years ago
ASCO Genitourinary Cancers Symposium (Olaparib and Durvalumab in metastatic castrate-resistant prostate cancer (mCRPC))
Prior treatment with
enzalutamide
and/or abiraterone is required. D is given at 1500 mg iv q28 days + O 300 mg tablets po q12 hours. The primary endpoint is PFS. Core biopsies undergo mutational analysis.
Prior treatment with
enzalutamide
and/or abiraterone is required. D is given at 1500 mg iv q28 days + O 300 mg tablets po q12 hours. The primary endpoint is PFS. Core biopsies undergo mutational analysis.
pjoshea13
in
Advanced Prostate Cancer
6 years ago
Bipolar Androgen Therapy in Men With Metastatic Castration-Resistant Prostate Cancer After Progression on Enzalutamide
http://www.practiceupdate.com/content/bipolar-androgen-therapy-in-men-with-metastatic-castration-resistant-prostate-cancer-after-progression-on-
enzalutamide
/62093/61/11/1
http://www.practiceupdate.com/content/bipolar-androgen-therapy-in-men-with-metastatic-castration-resistant-prostate-cancer-after-progression-on-
enzalutamide
/62093/61/11/1
snoraste
in
Advanced Prostate Cancer
6 years ago
1
...
34
35
36
...
39
Next page
10
20
30
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
712 results
Fight Prostate Cancer
49 results
Prostate Cancer Network
7 results
View top 10 communities
Sort by
Most Relevant
Newest